News and Press Releases

Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private...

Veristat’s Bold Thinking and World Class Clinical, Regulatory and Commercialization Capabilities Allow the Company to Successfully Tackle...

Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK...

Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical...

Cindy Henderson Named Veristat Chief Commercial Officer

Instrumental to Veristat’s growth, success, and client satisfaction over the last 15 years

Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of...

Providing sponsors expert staff to accelerate milestones and support study success

Veristat Expands its Expertise and Scale across Biopharma and Medtech

Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to...

Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021

Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases

Veristat Strengthens Regulatory Capabilities Across Europe and UK

Acquires Drug Development and Regulation (DDR), a regulatory consultancy led by former senior officer at European Medicines Agency (EMA)

Veristat Appoints Colleen Pelton Chief Talent Officer

Global Talent Executive to Advance Company’s Commitment to a Best-in-class Workforce

Veristat Announces New Investment Partner—WindRose Health Investors

Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients